Sirri Eunice, Castro Felipe Andres, Kieschke Joachim, Jansen Lina, Emrich Katharina, Gondos Adam, Holleczek Bernd, Katalinic Alexander, Urbschat Iris, Vohmann Claudia, Brenner Hermann
From the *Lower Saxony Cancer Registry, Oldenburg; †Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg; ‡Cancer Registry of Rhineland-Palatinate, Institute for Medical Biostatistics, Epidemiology and Informatics, University Medical Center, Johannes Gutenberg University Mainz, Mainz; §Saarland Cancer Registry, Saarbrücken; ∥Cancer Registry of Schleswig-Holstein, Lübeck; and ¶Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT); and #German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Pancreas. 2016 Jul;45(6):908-14. doi: 10.1097/MPA.0000000000000588.
Survival improvement for pancreatic cancer has not been observed in the last 4 decades. We report the most up-to-date population-based relative survival (RS) estimates and recent trends in Germany and the United States.
Data for patients diagnosed in 1997 to 2010 and followed up to 2010 were drawn from 12 population-based German cancer registries and the US SEER (Surveillance, Epidemiology and End Results) 13 registries database. Using period analysis, 5-year RS for 2007 to 2010 was derived. Model-based period analysis was used to assess 5-year RS time trends, 2002-2010.
In total 28,977 (Germany) and 34,793 (United States) patients aged 15 to 74 years were analyzed. Five-year RS was 10.7% and 10.3% in Germany and the United States, respectively, and strongly decreased with age and tumor spread. Prognosis slightly improved from the period 2002-2004 to 2008-2010 (overall age-adjusted RS: +2.5% units in Germany and +3.4% units in the United States); improvement was particularly strong for regional stage and head and body subsites in Germany and for localized and regional stages and tail subsite in the United States.
Although pancreatic cancer survival continues to be poor for advanced-stage patients, our study disclosed encouraging indications of first improvements in 5-year RS after decades of stagnation.
在过去40年中，胰腺癌患者的生存率未见提高。我们报告了德国和美国基于人群的最新相对生存率（RS）估计值及近期趋势。
数据来源于12个德国人群癌症登记处及美国监测、流行病学和最终结果（SEER）13个登记处数据库，研究对象为1997年至2010年确诊并随访至2010年的患者。采用期间分析得出2007年至2010年的5年RS。基于模型的期间分析用于评估2002 - 2010年5年RS的时间趋势。
总共分析了28,977例（德国）和34,793例（美国）年龄在15至74岁之间的患者。德国和美国的5年RS分别为10.7%和10.3%，且随年龄和肿瘤扩散程度显著降低。从2002 - 2004年到2008 - 2010年，预后略有改善（总体年龄调整后的RS：德国提高了2.5个百分点，美国提高了3.4个百分点）；德国在区域分期以及胰腺头部和体部亚部位改善尤为明显，美国在局部和区域分期以及胰腺尾部亚部位改善尤为明显。
尽管晚期胰腺癌患者的生存率仍然很低，但我们的研究揭示了令人鼓舞的迹象，即经过数十年停滞之后，5年RS首次出现改善。
